• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎细胞因子风暴的发病机制与治疗

Pathogenesis and treatment of cytokine storm in COVID-19.

作者信息

Soy Mehmet, Keser Gökhan, Atagündüz Pamir

机构信息

Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Altınbaş University, Bahçelievler Medical Park Hospital, İstanbul Turkey.

Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ege University, İzmir Turkey.

出版信息

Turk J Biol. 2021 Aug 30;45(4):372-389. doi: 10.3906/biy-2105-37. eCollection 2021.

DOI:10.3906/biy-2105-37
PMID:34803441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8573840/
Abstract

COVID-19 is a viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that killed a large number of patients around the world. A hyperinflammatory state resulting in a cytokine storm and adult respiratory distress syndrome seems to be the major cause of the death. Many mechanisms have been suggested in the pathogenesis of COVID-19 associated cytokine storm (COVID-CS). Insufficient viral clearance and persistence of a strong cytokine response despite inadequate antiviral immunity seem to be the main mechanisms underlying the pathogenesis. The diagnosis of COVID-19 is based on relatively constant clinical symptoms, clinical findings, laboratory tests, and imaging techniques, while the diagnosis of COVID-CS is a rather dynamic process, based on evolving or newly emerging findings during the clinical course. Management of COVID-19 consists of using antiviral agents to inhibit SARS-CoV-2 replication and treating potential complications including the cytokine storm together with general supportive measures. COVID-CS may be treated using appropriate immunosuppressive and immunomodulatory drugs that reduce the level of inappropriate systemic inflammation, which has the potential to cause organ damage. Currently corticosteroids, IL-6 blockers, or IL-1 blockers are most widely used for treating COVID-CS.

摘要

新型冠状病毒肺炎(COVID-19)是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的一种病毒感染,在全球造成大量患者死亡。导致细胞因子风暴和成人呼吸窘迫综合征的过度炎症状态似乎是死亡的主要原因。在新型冠状病毒肺炎相关细胞因子风暴(COVID-CS)的发病机制中,已提出多种机制。尽管抗病毒免疫力不足,但病毒清除不足和强烈的细胞因子反应持续存在似乎是发病机制的主要原因。COVID-19的诊断基于相对恒定的临床症状、临床发现、实验室检查和影像学技术,而COVID-CS的诊断是一个相当动态的过程,基于临床过程中不断演变或新出现的发现。COVID-19的治疗包括使用抗病毒药物抑制SARS-CoV-2复制,并治疗包括细胞因子风暴在内的潜在并发症以及一般支持措施。COVID-CS可使用适当的免疫抑制和免疫调节药物进行治疗,这些药物可降低不适当的全身炎症水平,而这种炎症可能导致器官损伤。目前,皮质类固醇、白细胞介素-6阻滞剂或白细胞介素-1阻滞剂最广泛用于治疗COVID-CS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cd/8573840/358affb77377/turkjbio-45-372-fig002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cd/8573840/8cf25bd82761/turkjbio-45-372-fig001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cd/8573840/358affb77377/turkjbio-45-372-fig002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cd/8573840/8cf25bd82761/turkjbio-45-372-fig001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cd/8573840/358affb77377/turkjbio-45-372-fig002.jpg

相似文献

1
Pathogenesis and treatment of cytokine storm in COVID-19.新型冠状病毒肺炎细胞因子风暴的发病机制与治疗
Turk J Biol. 2021 Aug 30;45(4):372-389. doi: 10.3906/biy-2105-37. eCollection 2021.
2
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者:一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
3
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
4
Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.早期识别 COVID-19 细胞因子风暴并使用阿那白滞素或托珠单抗治疗。
Int J Infect Dis. 2020 Oct;99:291-297. doi: 10.1016/j.ijid.2020.07.081. Epub 2020 Aug 6.
5
Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.托珠单抗治疗重症新型冠状病毒肺炎减轻细胞因子风暴并避免急性呼吸窘迫期间机械通气:病例报告及文献综述
Trop Med Infect Dis. 2020 Jul 3;5(3):112. doi: 10.3390/tropicalmed5030112.
6
Immunotherapy Summary for Cytokine Storm in COVID-19.新型冠状病毒肺炎细胞因子风暴的免疫治疗概述
Front Pharmacol. 2021 Sep 17;12:731847. doi: 10.3389/fphar.2021.731847. eCollection 2021.
7
Storm at the Time of Corona: A Glimpse at the Current Understanding and Therapeutic Opportunities of the SARS-CoV-2 Cytokine Storm.新冠疫情下的风暴:对 SARS-CoV-2 细胞因子风暴当前认识和治疗机会的一瞥。
Curr Pharm Des. 2021;27(13):1549-1552. doi: 10.2174/1381612826666201125102649.
8
Immune system response during viral Infections: Immunomodulators, cytokine storm (CS) and Immunotherapeutics in COVID-19.病毒感染期间的免疫系统反应:免疫调节剂、细胞因子风暴(CS)与COVID-19中的免疫疗法
Saudi Pharm J. 2021 Feb;29(2):173-187. doi: 10.1016/j.jsps.2020.12.018. Epub 2021 Jan 7.
9
Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses.影响COVID-19患者发病机制的多种免疫因素:关于病毒传播、对抗细胞因子风暴和炎症反应的免疫治疗选择的综述
Pathogens. 2021 May 7;10(5):565. doi: 10.3390/pathogens10050565.
10
Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.托珠单抗治疗 COVID-19 中的“细胞因子风暴综合征”:一例报告。
Acta Med Indones. 2021 Apr;53(2):194-201.

引用本文的文献

1
Antibody repertoire associated with clinically diverse presentations of pediatric SARS-CoV-2 infection.与儿童SARS-CoV-2感染临床多样表现相关的抗体库。
medRxiv. 2025 Jul 23:2025.07.22.25331300. doi: 10.1101/2025.07.22.25331300.
2
The impact of COVID-19 pandemic on the etiological spectrum of respiratory infections in children.新冠疫情对儿童呼吸道感染病因谱的影响。
Eur J Clin Microbiol Infect Dis. 2025 Jul 31. doi: 10.1007/s10096-025-05222-5.
3
Elevated serum mtDNA in COVID-19 patients is linked to SARS-CoV-2 envelope protein targeting mitochondrial VDAC1, inducing apoptosis and mtDNA release.

本文引用的文献

1
Systemic and organ-specific immune-related manifestations of COVID-19.COVID-19 的全身性和器官特异性免疫相关表现。
Nat Rev Rheumatol. 2021 Jun;17(6):315-332. doi: 10.1038/s41584-021-00608-z. Epub 2021 Apr 26.
2
Germline Genetic Variants of Viral Entry and Innate Immunity May Influence Susceptibility to SARS-CoV-2 Infection: Toward a Polygenic Risk Score for Risk Stratification.病毒进入和先天免疫的种系遗传变异可能影响 SARS-CoV-2 感染易感性:建立一种多基因风险评分以进行风险分层。
Front Immunol. 2021 Mar 8;12:653489. doi: 10.3389/fimmu.2021.653489. eCollection 2021.
3
Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19.
COVID-19 患者血清中的 mtDNA 升高与 SARS-CoV-2 包膜蛋白靶向线粒体 VDAC1 有关,后者诱导细胞凋亡和 mtDNA 释放。
Apoptosis. 2024 Dec;29(11-12):2025-2046. doi: 10.1007/s10495-024-02025-5. Epub 2024 Oct 7.
4
Hypochloremia: A Potential Indicator of Poor Outcomes in COVID-19.低氯血症:COVID-19 不良预后的潜在指标。
Medicina (Kaunas). 2024 Aug 29;60(9):1414. doi: 10.3390/medicina60091414.
5
Different polarization and functionality of CD4+ T helper subsets in people with post-COVID condition.不同极化和功能的 CD4+ T 辅助细胞亚群在新冠病毒感染后患者中的表现。
Front Immunol. 2024 Aug 27;15:1431411. doi: 10.3389/fimmu.2024.1431411. eCollection 2024.
6
Neutrophil-to-Lymphocyte Ratio and Cytokine Profiling as Predictors of Disease Severity and Survival in Unvaccinated COVID-19 Patients.中性粒细胞与淋巴细胞比值及细胞因子谱作为未接种疫苗的COVID-19患者疾病严重程度和生存的预测指标
Vaccines (Basel). 2024 Jul 31;12(8):861. doi: 10.3390/vaccines12080861.
7
Identification of biomarkers and pathways for the SARS-CoV-2 infections in obstructive sleep apnea patients based on machine learning and proteomic analysis.基于机器学习和蛋白质组学分析鉴定阻塞性睡眠呼吸暂停患者中 SARS-CoV-2 感染的生物标志物和途径。
BMC Pulm Med. 2024 Mar 5;24(1):112. doi: 10.1186/s12890-024-02921-1.
8
IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition.IgM N-糖基化与 COVID-19 严重程度和补体沉积率相关。
Nat Commun. 2024 Jan 9;15(1):404. doi: 10.1038/s41467-023-44211-0.
9
Unveiling COVID-19 Secrets: Harnessing Cytokines as Powerful Biomarkers for Diagnosis and Predicting Severity.揭开新冠病毒的秘密:利用细胞因子作为诊断和预测严重程度的强大生物标志物
J Inflamm Res. 2023 Dec 11;16:6055-6070. doi: 10.2147/JIR.S439217. eCollection 2023.
10
Effectiveness of Molnupiravir Treatment in Patients with COVID-19 in Korea: A Propensity Score Matched Study.莫努匹拉韦治疗韩国新冠肺炎患者的有效性:一项倾向评分匹配研究。
Infect Chemother. 2023 Dec;55(4):490-499. doi: 10.3947/ic.2023.0087. Epub 2023 Nov 22.
COVID-19 住院患者队列的四个月临床状况。
JAMA. 2021 Apr 20;325(15):1525-1534. doi: 10.1001/jama.2021.3331.
4
Vaccine efficacy probable against COVID-19 variants.疫苗可能对新冠病毒变异株有效。
Science. 2021 Mar 12;371(6534):1116. doi: 10.1126/science.abg9461.
5
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.白细胞介素-1和白细胞介素-6抑制与COVID-19合并高炎症患者标准治疗的比较:一项队列研究
Lancet Rheumatol. 2021 Apr;3(4):e253-e261. doi: 10.1016/S2665-9913(21)00012-6. Epub 2021 Feb 3.
6
SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)在人原代单核细胞中激活炎性小体并引发细胞焦亡。
Cell Death Discov. 2021 Mar 1;7(1):43. doi: 10.1038/s41420-021-00428-w.
7
Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19.秋水仙碱对新型冠状病毒肺炎死亡率及机械通气影响的荟萃分析
Am J Cardiol. 2021 Apr 15;145:170-172. doi: 10.1016/j.amjcard.2021.02.005. Epub 2021 Feb 19.
8
Interferon-based therapies in COVID-19.COVID-19中基于干扰素的疗法。
Int Immunopharmacol. 2021 Apr;93:107415. doi: 10.1016/j.intimp.2021.107415. Epub 2021 Jan 28.
9
Role of Toll-like receptors in the pathogenesis of COVID-19.Toll 样受体在 COVID-19 发病机制中的作用。
J Med Virol. 2021 May;93(5):2735-2739. doi: 10.1002/jmv.26826. Epub 2021 Feb 9.
10
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.阿那白滞素与常规治疗对新冠肺炎合并轻至中度肺炎成人住院患者的疗效(CORIMUNO-ANA-1):一项随机对照试验
Lancet Respir Med. 2021 Mar;9(3):295-304. doi: 10.1016/S2213-2600(20)30556-7. Epub 2021 Jan 22.